使用噬菌体治疗降低脊髓硬膜外脓肿发病率和死亡率的可行性。

IF 2.8 Q2 INFECTIOUS DISEASES
James B Doub, Jeremy Tran, Ryan Smith, Tyler Pease, Eugene Koh, Stephen Ludwig, Alina Lee, Ben Chan
{"title":"使用噬菌体治疗降低脊髓硬膜外脓肿发病率和死亡率的可行性。","authors":"James B Doub,&nbsp;Jeremy Tran,&nbsp;Ryan Smith,&nbsp;Tyler Pease,&nbsp;Eugene Koh,&nbsp;Stephen Ludwig,&nbsp;Alina Lee,&nbsp;Ben Chan","doi":"10.3947/ic.2022.0168","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates.</p><p><strong>Materials and methods: </strong>Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays.</p><p><strong>Results: </strong><i>Staphylococcus aureus</i> was the predominate bacterial cause (71%) and bacteremia was associated with 96% of <i>S. aureus</i> SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the <i>S. aureus</i> clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates.</p><p><strong>Conclusion: </strong>SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since <i>S. aureus</i> is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/e2/ic-55-257.PMC10323537.pdf","citationCount":"0","resultStr":"{\"title\":\"Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.\",\"authors\":\"James B Doub,&nbsp;Jeremy Tran,&nbsp;Ryan Smith,&nbsp;Tyler Pease,&nbsp;Eugene Koh,&nbsp;Stephen Ludwig,&nbsp;Alina Lee,&nbsp;Ben Chan\",\"doi\":\"10.3947/ic.2022.0168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates.</p><p><strong>Materials and methods: </strong>Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays.</p><p><strong>Results: </strong><i>Staphylococcus aureus</i> was the predominate bacterial cause (71%) and bacteremia was associated with 96% of <i>S. aureus</i> SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the <i>S. aureus</i> clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates.</p><p><strong>Conclusion: </strong>SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since <i>S. aureus</i> is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.</p>\",\"PeriodicalId\":51616,\"journal\":{\"name\":\"Infection and Chemotherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/e2/ic-55-257.PMC10323537.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3947/ic.2022.0168\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2022.0168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:本研究的目的是通过回顾单个机构中脊髓硬膜外脓肿(SEA)的原因和结果,并测试噬菌体对保存的SEA临床分离物的活性,来确定使用噬菌体治疗脊髓硬膜外脓肿(SEA)的可行性。材料和方法:回顾了在同一医疗中心接受SEA切口引流的患者的医疗记录。记录致病菌、合并菌血症发生率和结果。对保留临床分离株的SEA患者(N = 11)进行评估,以评估噬菌体治疗是否对这些分离株有足够的活性,如现场试验和生长抑制试验所见。结果:金黄色葡萄球菌为主要病原菌(71%),96%的金黄色葡萄球菌SEA伴有菌血症。超过50%的患者在三个月内死亡,感染复发,需要反复清创,或有长期后遗症。单个噬菌体对所有金黄色葡萄球菌临床分离株的斑点试验均呈阳性,对11株临床分离株中的9株(82%)抑制细菌生长超过24小时。结论:SEA与显著的死亡率和发病率相关,使其成为辅助噬菌体治疗的潜在适应症。由于金黄色葡萄球菌是SEA的主要病因,并且大多数病例都伴有菌血症,这为葡萄球菌噬菌体治疗创造了一个潜在的筛选和治疗平台,从而允许设计潜在的试点研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.

Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.

Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.

Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.

Background: The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates.

Materials and methods: Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays.

Results: Staphylococcus aureus was the predominate bacterial cause (71%) and bacteremia was associated with 96% of S. aureus SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the S. aureus clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates.

Conclusion: SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since S. aureus is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infection and Chemotherapy
Infection and Chemotherapy INFECTIOUS DISEASES-
CiteScore
6.60
自引率
11.90%
发文量
71
审稿时长
22 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信